Hi-dose re-irradiation helps breast cancer patients who have limited options
High-dose re-irradiation or second radiation therapy can help control cancer, and with moderate side effects in patients with locally recurrent refractory breast cancer, suggests a new Sunnybrook-led report published in the journal, Oncotarget.
Locally recurrent refractory breast cancer is disease that has returned after chemotherapy, surgical treatment and radiation therapy. The recurrence is confined to the breast or immediate surrounding area and is refractory or resistant to chemotherapy.
“Many patients, unfortunately, have limited options for treatment. They often go untreated and experience symptoms from local recurrence that significantly impact quality of life,” says Dr. Gregory Czarnota, radiation oncologist, Temerty Breast Cancer Centre, Sunnybrook’s Odette Cancer Centre.
Uncontrolled locally recurrent breast cancer can cause many significant problems that include ulcerations, bleeding, arm edema or excess watery fluid in the tissues, pain and brachial-plexus palsy or loss of movement or weakness of the arm.
The researchers observed and treated 47 women at an average age of 60 years, and followed them for overall survival (OS) for a median of 17.4 months. Overall survival was 73 percent at one year, and 67 at 2 years. Loco-regional cancer control was 63 percent at 1 year, and 50 percent at 2 years.
For most patients, the common side effect was acute radiation dermatitis at Grade 1 – 2, which ”is equivalent to slight redness of the skin,” says Dr. Czarnota.
In 2014, an estimated 24,400 Canadian women were diagnosed with breast cancer. Rates of breast cancer local recurrence after treatment are approximately 10 to 20% at 10 and 15 years respectively.